A Phase 3 interventional study of Acetylsalicylic acid and Placebo in Colorectal Cancer, sponsored by Anna Martling. Active, not recruiting at 32 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Anna Martling · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing aspirin in Colorectal Neoplasms — 1 open to participants now, 9 under way, 5 of them phase 3. Aspirin · Colorectal Neoplasms.
Among the 22 studies testing aspirin in Colorectal Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2016, is one of 7 in phase 3, and was the 11th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →1 of the 22 studies testing aspirin in Colorectal Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Instituto de Investigación Sanitaria Aragón · Sites in Spain
Ages 18–79
By country, each count listing its studies:
Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 10 · Phase 3 10 · Phase 4 1
First in 1992; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 626 is above the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 161 across the 22 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 22 has an industry lead sponsor. The 10 most frequent:
Anna Martling is the lead sponsor of 2 studies on the registry; none are open to participants now.
Anna Martling has 2 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing aspirin in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled, biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal cancer. Hypothesis is that patients diagnosed with colorectal cancer and somatic mutations in PI3K pathway can significantly improve survival if treated with low dose aspirin.
Patients with colorectal cancer clinical stage I-III will be screened for inclusion at the time of tumor surgery (at time of routine patient visit before elective surgery or postoperatively within 12 weeks in case of emergency procedure or if screening was missed preoperatively). After inclusion and when surgery is performed, patients with PIK3 mutations and stage II and III tumors will be randomized to receive 160 mg aspirin or placebo orally.
Last date for randomization and start of treatment is 12 weeks postoperatively. The treatment can be administered alone or in combination with adjuvant chemotherapy. The choice of any adjuvant chemotherapy is made by the Investigator and should follow the guidelines in the National Care Program. The treatment will be administered for 3 years. There will be a follow-up period for two years. Outside the trial, the patient will be treated according to standard care at the site.
A phone contact will be made 3 months after the randomization visit and thereafter every 6th month. The patients will also visit the site 6 months after randomization and thereafter every 6th month i.e. the patients will be in contact with the site every 3rd month. There will also be a visit/phone contact at the end of the follow-up period.
The primary objective is to determine whether adjuvant treatment with 160mg ASA once daily for 3 years can improve time to recurrence in participants with colorectal cancer with somatic alternations in the PI3K singling pathway.
UPDATE: New dimensional analysis and power calculation, 19th October 2020:
A total of 3900 patients will be screened in order to include 300 patients with PIK3CA (Exon 9 and 20) mutated tumors in each treatment arm (Group A). With an estimated 10 % drop-out rate, 150 patients will be randomized in each arm. This also includes approximately 15 % of the patients that will be excluded due to tumor stage 1.
An additional 300 patients with mutations in other PI3K pathway genes PIK3CA (other than exon 9 and 20), PIK3R1 or PTEN will also be randomized in each arm and will be treated as a separate group in the analyses (Group B). With an estimated 10 % drop-out rate, 150 patients will be randomized in each arm.
Patients already treated with ASA at inclusion will be included in an observation group.
An interim analysis will be made on safety i.e incidence and type of serious bleeding complication grade > 1 after 12 months. An independent safety data monitoring committee will be responsible for evaluating and follow-up of the safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One tablet acetylsalicylic acid (ASA) 160 mg, orally once daily for three years
Drug: Acetylsalicylic acid
One tablet placebo orally once daily for three years
Drug: Placebo
Also known as: ASA, aspirin
Time To Recurrence (TTR)
Number of participants with local recurrence, distant metastases or death from same cancer within 3 years from randomization
Time frame: 3 years
Disease Free Survival (DFS)
Number of participants with local recurrence, distant metastases, a new malignant neoplasm, or death from any cause within 3 years from randomization
Time frame: 3 years
Overall Survival (OS)
Death from any cause within 5 years from randomization
Time frame: 5 years
Frequency and Severity of Adverse Events (AE)
The frequency and severity of severe adverse events in the safety population
Time frame: 1 year and 3 years
First patient initial screening April 6, 2016. Last patient initial screening April 28, 2021. First patient randomized April 7, 2016. Last patient randomized July 19, 2021.
| Milestone | Aspirin | Placebo |
|---|---|---|
| Started | 313 | 313 |
| Completed | 311 | 312 |
| Not completed | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 |
Number of participants with local recurrence, distant metastases or death from same cancer within 3 years from randomization
| Participants | Aspirin | Placebo |
|---|---|---|
| Time To Recurrence (TTR) | 24 | 50 |
Number of participants with local recurrence, distant metastases, a new malignant neoplasm, or death from any cause within 3 years from randomization
| Participants | Aspirin | Placebo |
|---|---|---|
| Disease Free Survival (DFS) | 38 | 65 |
Death from any cause within 5 years from randomization
Results for this outcome have not been posted.
The frequency and severity of severe adverse events in the safety population
| Participants | Aspirin | Placebo |
|---|---|---|
| Severe adverse events | 52 | 36 |
| Non-severe adverse events | 134 | 110 |
Collected over From the date when a participant first received the study drug until end of follow-up (maximum 3 years from randomization), or until an outcome (recurrence/death), or until the participant dropped out of the trial.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aspirin | 25/309 (8.1%) | 52/309 (16.8%) | 134/309 (43.4%) |
| Placebo | 32/311 (10.3%) | 36/311 (11.6%) | 110/311 (35.4%) |
| Event | Aspirin | Placebo |
|---|---|---|
| IleusGastrointestinal disorders | 11/309 | 2/311 |
| Deep vein thrombosisVascular disorders | 9/309 | 7/311 |
| Pulmonary embolismVascular disorders | 4/309 | 3/311 |
| InjuryInjury, poisoning and procedural complications | 1/309 | 3/311 |
| Covid-19 infectionInfections and infestations | 2/309 | 0/311 |
| Death, unknown causeGeneral disorders | 2/309 | 0/311 |
| Ischemic strokeVascular disorders | 2/309 | 0/311 |
| Parastomal herniaGastrointestinal disorders | 2/309 | 0/311 |
| CholecystitisHepatobiliary disorders | 1/309 | 2/311 |
| Urinary tract infectionInfections and infestations | 1/309 | 2/311 |
| Event | Aspirin | Placebo |
|---|---|---|
| Adverse event of the gastrointestinal organ systemGastrointestinal disorders | 52/309 | 49/311 |
| Adverse event of the hematologic organ systemBlood and lymphatic system disorders | 51/309 | 33/311 |
| Adverse event of the skinSkin and subcutaneous tissue disorders | 20/309 | 18/311 |
| Musculoskeletal and Connective Tissue DisordersMusculoskeletal and connective tissue disorders | 18/309 | 20/311 |
| Age, Categorical(Participants) | Aspirin | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 147 | 140 | 287 |
| >=65 years | 166 | 173 | 339 |
| Sex: Female, Male(Participants) | Aspirin | Placebo | Total |
|---|---|---|---|
| Female | 164 | 160 | 324 |
| Male | 149 | 153 | 302 |
| Race and Ethnicity Not Collected(Participants) | Aspirin | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Aspirin | Placebo | Total |
|---|---|---|---|
| Sweden | 244 | 245 | 489 |
| Norway | 32 | 37 | 69 |
| Denmark | 19 | 14 | 33 |
| Finland | 18 | 17 | 35 |
| Tumour location(Participants) | Aspirin | Placebo | Total |
|---|---|---|---|
| Right colon | 137 | 142 | 279 |
| Left colon | 71 | 66 | 137 |
| Colon (side not specified) | 1 | 2 | 3 |
| Rectum | 104 | 103 | 207 |
| Somatic alteration(Participants) | Aspirin | Placebo | Total |
|---|---|---|---|
| PIK3CA exon 9/20 hotspot mutations | 157 | 157 | 314 |
| Other PI3K alterations | 156 | 156 | 312 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2016 to primary completion in Aug 2024, 100 months.
Results were first posted in Mar 2026, 1 year 7 months after primary completion.
Of 106 non-industry phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 116. This study's 100 months is above that.
Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aspirin
Anna Martling